vs
Side-by-side financial comparison of Aclarion, Inc. (ACON) and Celcuity Inc. (CELC). Click either name above to swap in a different company.
Aclarion, Inc. is a medical technology company focused on developing non-invasive solutions for chronic lower back pain diagnosis and treatment. Its core offerings leverage proprietary magnetic resonance spectroscopy technology to accurately identify painful intervertebral discs, serving healthcare providers and patients across the United States, with key focus on the chronic pain management and spinal care segments.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.5K | — | ||
| Q3 25 | $18.9K | — | ||
| Q2 25 | $19.3K | — | ||
| Q1 25 | $19.0K | — | ||
| Q4 24 | $10.2K | — | ||
| Q3 24 | $14.4K | — | ||
| Q2 24 | $11.0K | — | ||
| Q1 24 | $10.1K | — |
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $-1.7M | — | ||
| Q2 25 | $-1.6M | — | ||
| Q1 25 | $-2.0M | — | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $-1.4M | — | ||
| Q2 24 | $-1.2M | — | ||
| Q1 24 | $-2.4M | — |
| Q4 25 | 9.7% | — | ||
| Q3 25 | 23.2% | — | ||
| Q2 25 | 26.6% | — | ||
| Q1 25 | -23.6% | — | ||
| Q4 24 | -100.9% | — | ||
| Q3 24 | -48.1% | — | ||
| Q2 24 | -112.3% | — | ||
| Q1 24 | -92.6% | — |
| Q4 25 | -10785.8% | — | ||
| Q3 25 | -9666.2% | — | ||
| Q2 25 | -8988.6% | — | ||
| Q1 25 | -7856.0% | — | ||
| Q4 24 | -17652.7% | — | ||
| Q3 24 | -8995.3% | — | ||
| Q2 24 | -10350.6% | — | ||
| Q1 24 | -12609.3% | — |
| Q4 25 | -10223.7% | — | ||
| Q3 25 | -9008.0% | — | ||
| Q2 25 | -8285.9% | — | ||
| Q1 25 | -10728.4% | — | ||
| Q4 24 | -19444.6% | — | ||
| Q3 24 | -9482.7% | — | ||
| Q2 24 | -11285.0% | — | ||
| Q1 24 | -23720.6% | — |
| Q4 25 | $1.39 | — | ||
| Q3 25 | $-2.93 | — | ||
| Q2 25 | $-2.75 | — | ||
| Q1 25 | $-9.32 | — | ||
| Q4 24 | $-809.36 | — | ||
| Q3 24 | $-1321.49 | — | ||
| Q2 24 | $-1362.83 | — | ||
| Q1 24 | $-3985.22 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
